| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
Bacterial and algal cell membranes (surfactant action). Benzyldimethylstearylammonium chloride is a quaternary ammonium cationic surfactant that acts on bacterial and algal cell membranes. Its mechanism of action involves disruption of cell membrane integrity, leading to cell lysis and death. The compound exhibits potent bactericidal and algicidal capabilities. It does not exert selective embryopathic activity, indicating low embryotoxicity.
|
|---|---|
| ln Vitro |
Benzyldimethylstearylammonium chloride is effective against a wide range of bacteria and algae. It exhibits potent bactericidal and algicidal capabilities and remains resistant to acids, hard water, and inorganic salts. The compound exerts no selective embryopathic activity. Its in vitro activity includes disruption of microbial cell membranes, leading to cell death. As a surfactant, it also has detergent properties.
|
| ln Vivo |
In vivo studies of benzyldimethylstearylammonium chloride have shown that it exerts no selective embryopathic activity. The compound is used as a disinfectant and antiseptic in various industrial and research applications. It is not intended for therapeutic use in humans or animals. Further in vivo studies are needed to fully characterize its toxicity and safety profile.
|
| Enzyme Assay |
Non-cell-based assays for benzyldimethylstearylammonium chloride include antimicrobial susceptibility testing using broth microdilution or agar diffusion methods to determine minimum inhibitory concentrations (MICs) against bacterial and algal strains. Surfactant properties are assessed by measuring surface tension and critical micelle concentration (CMC). Embryopathic activity is assessed using standard embryotoxicity assays.
|
| Cell Assay |
Cell-based assays for benzyldimethylstearylammonium chloride use bacterial and algal cultures to assess antimicrobial activity. Cultures are treated with the compound at various concentrations, and growth inhibition is measured by optical density or colony counting. Cytotoxicity in mammalian cell lines can be assessed using standard cell viability assays to evaluate potential toxicity.
|
| Animal Protocol |
In vivo studies of benzyldimethylstearylammonium chloride are limited. The compound has been shown to exert no selective embryopathic activity. Toxicity studies may be conducted in animal models to assess safety for industrial and research applications. The compound is not intended for therapeutic use.
|
| ADME/Pharmacokinetics |
Benzyldimethylstearylammonium chloride has a molecular formula of C₂₇H₅₀ClN and a molecular weight of 424.15 g/mol. It is a quaternary ammonium cationic surfactant. The compound is effective against a wide range of bacteria and algae and exhibits potent bactericidal and algicidal capabilities. It should be stored under recommended conditions. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Toxicity Data
LC50 (Rat) = 3,280 mg/m³/4h Non-human Toxicity Values LD50 (Rat): Oral 1250 mg/kg LD50 (Rat): Intraperitoneal 280 mg/kg LD50 (Mice): Oral 760 mg/kg LD50 (Mice): Intraperitoneal 175 mg/kg LD50 (Guinea Pig): Oral 500 mg/kg Benzyldimethylstearylammonium chloride is a quaternary ammonium compound that exerts no selective embryopathic activity. It exhibits potent bactericidal and algicidal capabilities. The compound is not fully validated for medical applications and is intended for research use only. Standard laboratory safety practices should be followed when handling this compound. |
| References | |
| Additional Infomation |
Benzyldimethyloctadecylammonium chloride is a white solid or viscous liquid with a faint odor. (U.S. Coast Guard, 1999)
Benzyldimethylstearylammonium chloride (Stearyldimethylbenzylammonium chloride) is a quaternary ammonium cationic surfactant with the molecular formula C₂₇H₅₀ClN and a molecular weight of 424.15 g/mol. It is effective against a wide range of bacteria and algae and exhibits potent bactericidal and algicidal capabilities. The compound remains resistant to acids, hard water, and inorganic salts. It exerts no selective embryopathic activity. It is used in industrial applications as a disinfectant, antiseptic, and surfactant and is for research use only. |
| Molecular Formula |
C27H50CLN
|
|---|---|
| Molecular Weight |
424.15
|
| Exact Mass |
423.363
|
| CAS # |
122-19-0
|
| Related CAS # |
37612-69-4 (Parent)
|
| PubChem CID |
31204
|
| Appearance |
White to off-white solid powder
|
| Density |
0.98
|
| Boiling Point |
100ºC
|
| Melting Point |
54-56ºC
|
| Flash Point |
94ºC
|
| LogP |
5.528
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
29
|
| Complexity |
316
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1.[Cl-]
|
| InChi Key |
SFVFIFLLYFPGHH-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C27H50N.ClH/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-22-25-28(2,3)26-27-23-20-19-21-24-27;/h19-21,23-24H,4-18,22,25-26H2,1-3H3;1H/q+1;/p-1
|
| Chemical Name |
benzyl-dimethyl-octadecylazanium;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (294.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3577 mL | 11.7883 mL | 23.5766 mL | |
| 5 mM | 0.4715 mL | 2.3577 mL | 4.7153 mL | |
| 10 mM | 0.2358 mL | 1.1788 mL | 2.3577 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT02214121
Conditions:Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell DiseaseProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
